G1 Therapeutics Inc (GTHX)

$2.88

+0.01

(+0.35%)

Market is closed - opens 7 PM, 13 Jun 2024

Insights on G1 Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 14.87M → 14.47M (in $), with an average decrease of 2.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -18.20M → -10.21M (in $), with an average increase of 36.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 78.6% return, outperforming this stock by 72.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.8% return, outperforming this stock by 322.5%

Performance

  • $2.84
    $3.02
    $2.88
    downward going graph

    1.56%

    Downside

    Day's Volatility :6.13%

    Upside

    4.64%

    downward going graph
  • $1.08
    $6.14
    $2.88
    downward going graph

    62.5%

    Downside

    52 Weeks Volatility :82.41%

    Upside

    53.09%

    downward going graph

Returns

PeriodG1 Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-13.55%
-0.5%
0.0%
6 Months
-23.06%
9.6%
0.0%
1 Year
5.9%
11.8%
0.0%
3 Years
-87.38%
17.5%
-24.3%

Highlights

Market Capitalization
151.1M
Book Value
$0.53
Earnings Per Share (EPS)
-0.6
PEG Ratio
0.0
Wall Street Target Price
8.5
Profit Margin
-36.4%
Operating Margin TTM
-62.5%
Return On Assets TTM
-10.81%
Return On Equity TTM
-84.13%
Revenue TTM
84.0M
Revenue Per Share TTM
1.62
Quarterly Revenue Growth YOY
11.799999999999999%
Gross Profit TTM
47.6M
EBITDA
-22.3M
Diluted Eps TTM
-0.6
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.54
EPS Estimate Next Year
-0.3
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    83%Buy
    8%Hold
    8%Sell
Based on 12 Wall street analysts offering stock ratings for G1 Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 195.14%

Current $2.88
Target $8.50

Technicals Summary

Sell

Neutral

Buy

G1 Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
G1 Therapeutics Inc
G1 Therapeutics Inc
-37.88%
-23.06%
5.9%
-87.38%
-84.46%
Moderna, Inc.
Moderna, Inc.
18.08%
90.15%
20.13%
-28.46%
810.37%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.44%
16.99%
34.02%
91.12%
230.07%
Novo Nordisk A/s
Novo Nordisk A/s
7.08%
47.38%
78.63%
235.88%
440.46%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
12.0%
34.61%
41.38%
147.19%
182.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
G1 Therapeutics Inc
G1 Therapeutics Inc
NA
NA
0.0
-0.54
-0.84
-0.11
NA
0.53
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.16
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.56
29.56
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.53
49.53
2.36
3.48
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.34
31.34
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
G1 Therapeutics Inc
G1 Therapeutics Inc
Buy
$151.1M
-84.46%
NA
-36.4%
Moderna, Inc.
Moderna, Inc.
Buy
$56.9B
810.37%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.4B
230.07%
29.56
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$639.8B
440.46%
49.53
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.7B
182.21%
31.34
39.46%

Institutional Holdings

  • Vanguard Group Inc

    3.98%
  • Susquehanna International Group, LLP

    3.02%
  • D. E. Shaw & Co LP

    1.50%
  • BlackRock Inc

    1.30%
  • Renaissance Technologies Corp

    1.21%
  • Raymond James & Associates

    1.08%

Company Information

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.

Organization
G1 Therapeutics Inc
Employees
100
CEO
Mr. John E. Bailey Jr.
Industry
Health Technology

FAQs